Cytori Therapeutics Inc., of Austin, Texas, is changing its name to Plus Therapeutics Inc. to reflect its new focus on developing innovative drugs. It has reserved a new stock symbol, PSTV, and plans to submit notice of the company name change to Nasdaq.
Seattle Genetics Inc., of Bothell, Wash., reported U.S. and Canadian sales of Adcetris (brentuximab vedotin), its antibody-drug conjugate targeting CD30 for lymphoma, totaling $159 million for the second quarter, marking a 30% increase over net sales in the second quarter of 2018 and topping consensus estimates by roughly 7%.
Adverum Biotechnologies Inc., of Menlo Park, Calif., appointed Carol Hoang vice president, medical affairs and James Shahbazian vice president, finance.
Given improvements that Basel, Switzerland-based Novartis AG made to its patient access program for Kisqali (ribociclib), the U.K.'s National Institute for Health and Care Excellence (NICE) is recommending the drug, used with fulvestrant chemotherapy, as an option for people with hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer who have had previous endocrine therapy.
Neuralstem Inc., of Germantown, Md., completed a reverse stock split of its shares of common stock at a ratio of 1-for-20. The reverse stock split becomes effective Wednesday. The split enables Neuralstem to regain compliance with the $1 minimum bid price condition of Nasdaq.
Eyenovia Inc., of New York, said it closed its underwritten public offering of 4.38 million shares of common stock at $2.78 each for net proceeds of approximately $11.2 million.
RSS